CA2546321A1 - Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle - Google Patents

Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle Download PDF

Info

Publication number
CA2546321A1
CA2546321A1 CA002546321A CA2546321A CA2546321A1 CA 2546321 A1 CA2546321 A1 CA 2546321A1 CA 002546321 A CA002546321 A CA 002546321A CA 2546321 A CA2546321 A CA 2546321A CA 2546321 A1 CA2546321 A1 CA 2546321A1
Authority
CA
Canada
Prior art keywords
dosage form
lipid
composition
suspending vehicle
amphiphilic molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA002546321A
Other languages
French (fr)
Inventor
Rom Ezer Eliaz
Yuanpeng Zhang
Catherine Manya Rohloff
Eric William Weeks
Gunjan Junnarkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Alza Corporation
Rom Ezer Eliaz
Yuanpeng Zhang
Catherine Manya Rohloff
Eric William Weeks
Gunjan Junnarkar
Intarcia Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation, Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar, Intarcia Therapeutics, Inc. filed Critical Alza Corporation
Publication of CA2546321A1 publication Critical patent/CA2546321A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Abstract

A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

Claims (82)

1. A liquid composition in an osmotic drug delivery system comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.
2. The composition of claim 1 wherein the amphiphilic molecule is selected from lipid, surfactant, amphiphilic block polymer, or amphiphilic proteins or peptides.
3. The composition of claim 2 wherein the lipid is selected from saturated lipid, unsaturated lipid, neutral lipid, anionic lipid, cationic lipid, natural lipid or synthetic lipid.
4. The composition of claim 1, wherein said pharmaceutically active agent is suspended in a particle within said liquid composition.
5. The composition of claim 3, wherein the lipid is selected from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidic acid (PA), or sphingomyelin (SM).
6. The composition of claim 3, wherein the neutral lipid is selected from dioleoyl phosphatidylcholine (DOPC), dimyritoylphosphatidylcholine (DMPC), dipalinitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), egg phosphatidylcholine (egg PC), soy phosphatidylcholine (soy PC), partially or fully hydrogenated phosphatidylcholins (PHSPC or HSPC), palinitoyl-oleoyl phosphatidylcholine (POPC), or stearyloleoylphosphatidylcholine (SOPC).
7. The composition of claim 3, wherein the anionic lipid is selected from dioleoy phosphatidylglycerol (DOPG), dimyritoylphosphatidylglycerol (DMPG), dipalinitoylphosphatidylglycerol (DPPG), or distearoylphosphatidylglycerol (DSPG).
8. The composition of claim 1, wherein the non-aqueous liquid solvent is selected from lauryl lactate (LL), lauryl alcohol (LA), benzyl alcohol (BA), benzyl benzoate (BB), 1:1 benzyl benzoate: benzyl alcohol, benzyl alcohol, ethyl hexyl lactate, glycerol formal, tetraglycol (glycofurol; GF), N-1-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide, (DMSO), polyethyleneglycol (e.g., PEG 400), triglycerides (triolein, trilaurin, tricarprin, tricaprylin), ethanol, isopropanol, t-butyl alcohol, cyclohexanol, glycerin, glycerol, .alpha.-tocopherol (vitamin E) vegetable oil, sesame oil, soybean oil, cottonseed oil or peanut oil.
9. The composition of claim 1, further comprising polyethyleneglycol (PEG)-lipid compound selected from mPEG-DPPE, mPEG-DMPE, mPEG-DSPE, mPEG-ceramide-DSPE, or mPEG-DS.
10. The composition of claim 1, further comprising block copolymer surfactants selected from Pluronic® surfactants or Pluronic® surfactant F-127, or further comprising sorbitan ester structurants selected from sorbitan di-isostearate, sorbitan dioleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalinitate, sorbitan monostearate, sorbitan sesqui-isostearate, sorbitan sesquioleate, sorbitan trioleate, sorbitan sesquistearate, sorbitan tri-isostearate, sorbitan tristearate, or sorbitan tristearate.
11. The composition of claim 1, further comprising an anti-oxidant lipid compound selected from vitamin E, .alpha.-tocopherol, or ascorbic acid.
12. The composition of claim 1 wherein the pharmaceutically active agent is selected from a protein, peptide, small molecule drug, lipid drug or nucleic acid drug, DNA
drug, RNA drug, antisense drug, ribozyme drug, DNAzyme drug.
13. The composition of claim 1 wherein an amphiphilic molecule weight percent is from about 1 to about 100 weight percent.
14. The composition of claim 1 wherein the non-aqueous liquid solvent weight percent is from about 0 to about 99 weight percent.
15. The composition of claim 1, wherein the composition is a viscous liquid composition.
16. The composition of claim 15 wherein viscosity of the composition is from about 1 to about 100,000 poise.
17. The composition of claim 1 wherein a ratio by weight of amphiphilic molecule to non-aqueous liquid solvent is between about 1 and about 4.
18. The composition of claim 1 wherein the pharmaceutically active agent is combined with sucrose, methionine and citrate in weight ratios of 1 to 2 to 1 to 2.15.
19. The composition of claim 12, wherein the pharmaceutically active agent is selected from biologically or pharmacologically active substance.
20. The composition of claim 19, wherein the pharmaceutically active agent is .omega.-interferon, .alpha.-interferon, .beta.-interferon, .gamma.- interferon, erythropoietin, human growth hormone, granulocyte macrophage colony stimulating factor (GM-CSF), human growth hormone releasing hormone (huGHRH), insulin, desmopressin, infliximab, antibody or an agent conjugated to a targeting ligand, risperidone, paliperidone, glucagon-like peptide-1 (GLP-1), or bone morphogenic proteins.
21. A dosage form for osmotic drug,delivery comprising:
a capsule including a first chamber containing a viscous liquid pharmaceutical composition and a second chamber containing an osmotic agent, said first chamber having an opening through which the pharmaceutical composition can be delivered from the first chamber to a location external of the first chamber;
a movable separating member positioned in the capsule between the first chamber and the second chamber;
a wall of the second chamber including a fluid permeable portion allowing fluid to pass from a surrounding environment into the second chamber; and an incompressible fluid additive located within the second chamber and substantially surrounding the osmotic agent.
22. The dosage form of claim 21, wherein the viscous liquid pharmaceutical composition comprises an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.
23. The dosage form of claim 22 wherein the amphiphilic molecule is selected from lipid, surfactant, amphiphilic block polymer, or amphiphilic proteins or peptides.
24. The dosage form of claim 23 wherein the lipid is selected from saturated lipid, unsaturated lipid, neutral lipid, or anionic lipid.
25. The dosage form of claim 22, wherein said pharmaceutically active agent is suspended in a particle within said liquid composition.
26. The dosage form of claim 24, wherein the lipid is selected from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphosphatidylinositol (PI), phosphatidylserine (PS), phosphatidic acid (PA), or sphingomyelin (SM).
27. The dosage form of claim 24, wherein the neutral lipid is selected from dioleoyl phosphatidylcholine (DOPC), dimyritoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), egg phosphatidylcholine (egg PC), soy phosphatidylcholine (soy PC), partially or fully hydrogenated phosphatidylcholins (PHSPC or HSPC), palinitoyl-oleoyl phosphatidylcholine (POPC), or stearyloleoylphosphatidylcholin (SOPC).
28. The dosage form of claim 24, wherein the anionic lipid is selected from dioleoy phosphatidylglycerol (DOPG), dimyritoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), or distearoylphosphatidylglycerol (DSPG).
29. The dosage form of claim 22, wherein the non-aqueous liquid solvent is selected from lauryl lactate (LL), lauryl alcohol (LA), benzyl alcohol (BA), benzyl benzoate (BB), 1:1 benzyl benzoate: benzyl alcohol, benzyl alcohol, ethyl hexyl lactate, glycerol formal, tetraglycol (glycofurol; GF), N-1-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide, (DMSO), polyethyleneglycol (e.g., PEG 400), triglycerides (triolein, trilaurin, tricarprin, tricaprylin), ethanol, isopropanol, t-butyl alcohol, cyclohexanol, glycerin, glycerol, .alpha.-tocopherol (vitamin E) vegetable oil, sesame oil, soybean oil, cottonseed oil or peanut oil.
30. The dosage form of claim 22 wherein the pharmaceutically active agent is selected from a protein, peptide, small molecule drug, lipid drug, or prodrug conjugated to lipid.
31. The dosage form of claim 21 wherein an amphiphilic molecule weight percent is from about 1 to about 100 weight percent.
32. The dosage form of claim 21 wherein a non-aqueous liquid solvent weight percent is from about 0 to about 99 weight percent.
33. The dosage form of claim 21 wherein viscosity of the composition is from about 1 to about 100,000 poise.
34. The dosage form of claim 21 wherein a ratio by weight of amphiphilic molecule to non-aqueous liquid solvent is between about 1 and about 4.
35. The dosage form of claim 21, wherein the osmotic agent is in a tabular form and the fluid additive surrounds the tabular osmotic agent.
36. The dosage form of claim 21, wherein the separating member is a slidable piston.
37. The dosage form of claim 21, wherein the fluid permeable portion is a membrane.
38. The dosage form of claim 21, wherein the osmotic agent is a tablet.
39. The dosage form of claim 21, wherein the fluid additive is a lubricating liquid for preventing freeze-up of the osmotic agent.
40. The dosage form of claim 21, wherein the fluid additive is a gel.
41. The dosage form of claim 21, wherein the fluid additive includes PEG.
42. The dosage form according to claim 21, including at least one gap between an inner surface of the capsule and the osmotic agent, said fluid additive filling the at least one gap to improve start-up time.
43. The dosage form according to claim 21, wherein the osmotic agent includes NaCl and the fluid additive includes PEG.
44. A suspending vehicle in a pump-driven dosage form comprising an amphiphilic molecule, a non-aqueous solvent, and a performance modifier.
45. The suspending vehicle of claim 44 which is substantially non-aqueous.
46. The suspending vehicle of claim 44 wherein the amphiphilic molecule comprises a lipid.
47. The suspending vehicle of claim 46 wherein the lipid is dioleoyl phosphatidylcholine (DOPC), dimyritoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), egg phosphatidylcholine (egg PC), soy phosphatidylcholine (soy PC), partially hydrogenated phosphatidylcholins (PHSPC), fully hydrogenated phosphatidylcholins (HSPC), palinitoyl-oleoyl phosphatidylcholine (POPC), or stearyloleoylphosphatidylcholine (SOPC).
48. The suspending vehicle of claim 44 which is substantially free of stiff gels.
49. The suspending vehicle of claim 48 which is substantially free of stiff gels upon contact with an aqueous medium.
50. The suspending vehicle of claim 44 which has improved rheological properties as compared to a suspending vehicle which does not contain the performance modifier.
51. The suspending vehicle of claim 50 which has a change in viscosity of less than or equal to a factor of 10 in combination with a 10% by weight change in amount of the amphiphilic molecule in the suspending vehicle.
52. The suspending vehicle of claim 44 wherein a weight ratio of the non-aqueous solvent to the performance modifier is from about 1:0.33 to about 1:0.001.
53. The suspending vehicle of claim 44 wherein a weight ratio of the amphiphilic molecule to the performance modifier is from about 0.67:1 to about 1.5:1.
54. The suspending vehicle of claim 44 wherein a weight ratio of the amphiphilic molecule to a combination of the performance modifier and the non-aqueous solvent is from about 0.75:1 to about 1.22:1.
55. The suspending vehicle of claim 46 wherein the lipid comprises dioleoyl phosphatidylcholine (DOPC), the non-aqueous solvent comprises a-tocopherol, and the performance modifier comprises ethanol, sesame oil, ethyl acetate, or combinations thereof.
56. A kit comprising the suspending vehicle of claim 44 and instructions for suspending or dispersing a pharmaceutically active agent therein to create a pharmaceutical suspension.
57. The kit of claim 56 further comprising a dosage form and instructions for loading the dosage form with the pharmaceutical suspension.
58. A method comprising:
identifying an amphiphilic molecule;
identifying a non-aqueous solvent;
identifying a performance modifier;
mixing the amphiphilic molecule, the non-aqueous solvent, and the performance modifier to create a suspending vehicle.
59. The method of claim 58 wherein the performance modifier improves rheological properties of the suspending vehicle as compared to a suspending vehicle which does not contain the performance modifier.
60. The method of claim 58 comprising substantially dissolving or dispersing the amphiphilic molecule in the performance modifier to create a mixture; and combining the non-aqueous solvent with the mixture to create a suspending vehicle.
61. The method of claim 60 wherein the amphiphilic molecule dissolves more quickly in a combination of the non-aqueous solvent and the performance modifier as compared to dissolution in only the non-aqueous solvent.
62. The method of claim 58 further comprising adding a pharmaceutically active agent to the suspending vehicle to create a pharmaceutical suspension.
63. The method of claim 62 further comprising adding the pharmaceutical suspension to a dosage form.
64. The method of claim 63 wherein the dosage form comprises a first wall that maintains its physical and chemical integrity during the life of the dosage form and is substantially impermeable to a pharmaceutical suspension; a second wall that is partially permeable to an exterior fluid; a compartment defined by the first wall and the second wall;
and an exit port in the wall in communication with the compartment; and wherein the pharmaceutical suspension is positioned within the compartment.
65. The method of claim 64 wherein the dosage form further comprises an osmotic pump.
66. The method of claim 58 further comprising vortexing the mixture.
67. The method of claim 66 further comprising heating the suspending vehicle to a temperature of from about 100°C to about 120°C.
68. A suspension in a pump-driven dosage form comprising a pharmaceutically active agent suspended or dispersed in a suspending vehicle, wherein the suspending vehicle comprises an amphiphilic molecule, a non-aqueous solvent, and a performance modifier.
69. The suspension of claim 68 wherein the suspending vehicle has a viscosity of from about 1 to about 1,000,000 poise.
70. The suspension of claim 69 wherein the viscosity is from about 5 to about 100,000 poise.
71. The suspension of claim 68 wherein the amphiphilic molecule comprises a lipid.
72. The suspension of claim 71 wherein the lipid is dioleoyl phosphatidylcholine (DOPC), dimyritoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), egg phosphatidylcholine (egg PC), soy phosphatidylcholine (soy PC), partially hydrogenated phosphatidylcholins (PHSPC), fully hydrogenated phosphatidylcholins (HSPC), palmitoyl-oleoyl phosphatidylcholine (POPC), or stearyloleoylphosphatidylcholine (SOPC).
73. The suspension of claim 71 wherein the lipid comprises dioleoyl phosphatidylcholine (DOPC), the non-aqueous solvent comprises .alpha.-tocopherol, and the performance modifier comprises ethanol, sesame oil, ethyl acetate, or combinations thereof.
74. The suspension of either claim 68 or claim 73 wherein the pharmaceutically active agent comprises .omega.-interferon.
75. A dosage form comprising:
a first wall that maintains its physical and chemical integrity during the life of the dosage form and is substantially impermeable to a pharmaceutical suspension;
a second wall that is partially permeable to an exterior fluid;
a compartment defined by the first wall and the second wall;

a pharmaceutical suspension that is positioned within the compartment and comprises an amphiphilic molecule, a non-aqueous solvent, a performance modifier, and a pharmaceutically active agent; and an exit port in the wall in communication with the compartment.
76. The dosage form of claim 75 further comprising an osmotic pump.
77. The dosage form of claim 75 wherein upon contact with an aqueous medium, the pharmaceutical suspension is flowable through the exit port.
78. The dosage form of claim 76 wherein upon contact with an aqueous medium, the pharmaceutical suspension is flowable through the exit port under a force exerted by the osmotic pump under normal operating conditions.
79. The dosage form of claim 75 wherein the pharmaceutical suspension is substantially free of stiff gels upon contact with an aqueous medium.
80. The dosage form of claim 75 wherein the pharmaceutical suspension is substantially homogeneous for at least 3 months at 37°C.
81. A method comprising administering the dosage form of claim 75 to a mammal.
82. A kit comprising a dosage form of claim 75 and instructions for administering the dosage form.
CA002546321A 2003-11-17 2004-11-16 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle Withdrawn CA2546321A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52060503P 2003-11-17 2003-11-17
US60/520,605 2003-11-17
US10/988,716 US7731947B2 (en) 2003-11-17 2004-11-15 Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US10/988,716 2004-11-15
PCT/US2004/038409 WO2005048952A2 (en) 2003-11-17 2004-11-16 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle

Publications (1)

Publication Number Publication Date
CA2546321A1 true CA2546321A1 (en) 2005-06-02

Family

ID=34594998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002546321A Withdrawn CA2546321A1 (en) 2003-11-17 2004-11-16 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle

Country Status (15)

Country Link
US (6) US7731947B2 (en)
EP (2) EP1689363A4 (en)
JP (1) JP4824574B2 (en)
KR (1) KR20060123160A (en)
AR (1) AR046844A1 (en)
AU (1) AU2004291162B2 (en)
BR (1) BRPI0416613A (en)
CA (1) CA2546321A1 (en)
IL (1) IL175606A (en)
MX (1) MXPA06005565A (en)
NO (1) NO20062867L (en)
NZ (1) NZ547079A (en)
PE (1) PE20050926A1 (en)
TW (1) TW200534863A (en)
WO (1) WO2005048952A2 (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
CN1668279A (en) * 2002-06-17 2005-09-14 阿尔萨公司 Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006521897A (en) * 2003-03-31 2006-09-28 アルザ・コーポレーション Osmotic pump with means for dissipating internal pressure
AU2004227986A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
CA2523267C (en) 2003-04-23 2013-09-03 Biovalve Technologies, Inc. Hydraulically actuated pump for long duration medicament administration
BRPI0414193A (en) * 2003-09-09 2006-10-31 3M Innovative Properties Co antimicrobial composition, antimicrobial kit and methods of using the composition and applying an antimicrobial composition to a substrate
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US20050084471A1 (en) * 2003-09-09 2005-04-21 3M Innovative Properties Company Concentrated antimicrobial compositions and methods
CA2537811A1 (en) * 2003-10-31 2005-05-19 Alza Corporation Osmotic pump with self-retaining, fast-start membrane plug
CA2545027A1 (en) * 2003-11-06 2005-05-26 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
ES2343641T3 (en) 2005-01-14 2010-08-05 Camurus Ab TOPIC BIOADHESIVE FORMULATIONS.
ATE501710T1 (en) 2005-01-14 2011-04-15 Camurus Ab SOMATOSTATIN ANALOG FORMULATIONS
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
EP2361630A1 (en) * 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantable drug delivery device comprising particles and an osmotic pump
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
MX2007010904A (en) * 2005-03-10 2007-12-05 3M Innovative Properties Co Antimicrobial pet wipes and methods.
US8476319B2 (en) * 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
EP1898900B1 (en) * 2005-03-10 2011-06-08 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
PL1888031T3 (en) * 2005-06-06 2013-04-30 Camurus Ab Glp-1 analogue formulations
AR055099A1 (en) * 2005-07-28 2007-08-08 Alza Corp LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
EP2241327A1 (en) * 2006-03-15 2010-10-20 Novo Nordisk A/S Mixtures of Amylin and Insulin
DE102006013531A1 (en) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Drug delivery system, useful for supplying active substance to central nervous system of a mammal over the blood-brain barrier, comprises: nanoparticles of poly(DL-lactide-co-glycolide) and pharmaceutical substance e.g. cytostatic agent
CN103239773B (en) 2006-03-30 2015-08-26 瓦莱里塔斯公司 Multi-cartridge fluid delivery device
CN101453982B (en) * 2006-05-30 2011-05-04 精达制药公司 Two-piece, internal-channel osmotic delivery system flow modulator
ES2422864T3 (en) * 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
RU2440097C2 (en) * 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it
EP2164518B1 (en) * 2007-05-25 2019-04-24 The University Of British Columbia Formulations for the oral administration of therapeutic agents and related methods
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
PL2020221T3 (en) * 2007-06-19 2012-07-31 Neubourg Skin Care Gmbh & Co Kg DMS (Derma Membrane Structure) in foaming creams
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
KR100970911B1 (en) * 2007-12-13 2010-07-20 재단법인서울대학교산학협력재단 External preparation comprising triazole derivative antifungal agent and preparation method thereof
US20110052738A1 (en) * 2008-01-17 2011-03-03 Gary Dean Bennett Topical pain formulation
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
NZ592113A (en) * 2008-10-15 2012-04-27 Intarcia Therapeutics Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
WO2011005310A1 (en) * 2009-07-07 2011-01-13 Robert Shorr Pharmaceutical composition
EP3323423B1 (en) * 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
ES2742525T3 (en) 2009-10-01 2020-02-14 Adare Pharmaceuticals Us L P Orally administered corticosteroid compositions
US8546593B2 (en) * 2009-10-16 2013-10-01 Copperhead Chemical Company, Inc. Methods and compositions for novel liquid crystal delivery systems
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
US8853269B2 (en) * 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
WO2011138802A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution
US9468638B2 (en) * 2010-09-24 2016-10-18 Texas Southern University Itraconazole formulations
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012144943A1 (en) * 2011-04-18 2012-10-26 Lipidor Ab Liquid carrier for oral delivery of a pharmacologically active agent
JP6068443B2 (en) * 2011-04-27 2017-01-25 アイエスピー インヴェストメンツ インコーポレイテッドＩｓｐ Ｉｎｖｅｓｔｍｅｎｔｓ Ｉｎｃ． Clear wet spray and gel
SE1300709A1 (en) * 2013-11-14 2015-05-15 Lipidor Ab Composition and method of topical treatment
DE102011103948A1 (en) * 2011-06-06 2012-12-06 B. Braun Melsungen Ag Biopassivating coating of vascular prostheses with phospholipids containing nitrocarboxylic acids
WO2012174481A1 (en) * 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
KR101494594B1 (en) 2011-08-30 2015-02-23 주식회사 종근당 Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
IN2014DN06911A (en) * 2012-01-31 2015-05-15 Santen Pharmaceutical Co Ltd
US9452198B2 (en) * 2012-04-23 2016-09-27 Massachusetts Institute Of Technology Lectin conjugates for mucin hydration
US8822423B2 (en) 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
KR102139080B1 (en) 2012-05-25 2020-07-29 카무러스 에이비 Somatostatin receptor agonist formulations
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
JP6417327B2 (en) * 2012-07-26 2018-11-07 カムルス エービー Opioid formulation
KR101586791B1 (en) 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of GnRH analogues and pharmaceutical composition comprising the same
KR101586789B1 (en) * 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same
KR101586790B1 (en) 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
BR102015027955B1 (en) 2014-11-11 2021-03-09 Colgate-Palmolive Company method of making a composition for oral hygiene
WO2016130498A1 (en) 2015-02-10 2016-08-18 Massachusetts Institute Of Technology Isolated mucins and different microoorganisms, and methods of use
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
KR20180054627A (en) 2015-09-21 2018-05-24 테바 파마슈티컬스 인터내셔널 게엠베하 Sustained-release olanzapine preparation
WO2017100580A1 (en) * 2015-12-10 2017-06-15 Aaron Seitz Sphingolipid coatings and process for manufacturing sphingolipid coatings effective for inhibiting biofilm formation
CN105483076B (en) 2015-12-23 2019-01-25 中国科学院生物物理研究所 A kind of preparation method and applications of fat-body
WO2017119928A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
US10335405B1 (en) * 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
TWI728172B (en) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 Methods of treating eosinophilic esophagitis
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
CN116650678A (en) 2017-07-07 2023-08-29 德雷克塞尔大学 Voltage activated therapeutic, diagnostic and/or diagnostic constructs
CN111195348A (en) * 2018-11-19 2020-05-26 南京济群医药科技股份有限公司 Somatostatin nanosuspension and preparation method thereof
CA3180468A1 (en) 2020-06-30 2022-01-06 Jin Young Ko Injectable composition comprising gnrh analogue
RU2746320C1 (en) * 2020-07-27 2021-04-12 Сергей Николаевич Таргонский Method for producing lipid mixture and liposomal oral antiviral therapeutic and prophylactic agent using said lipid mixture
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (519)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR640907A (en) 1927-06-25 1928-07-24 Automatic flow limiter
US2168437A (en) 1935-04-10 1939-08-08 Kenneth O Buercklin Injection device
US2110208A (en) 1937-02-12 1938-03-08 U S Standard Products Company Antigen preparations
US3025991A (en) 1960-05-23 1962-03-20 Carron Products Co Bottle stopper
GB1049104A (en) 1963-05-11 1966-11-23 Prodotti Antibiotici Spa Pharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics
US3122162A (en) 1963-06-20 1964-02-25 Asa D Sands Flow control device
US3632768A (en) 1969-10-02 1972-01-04 Upjohn Co Therapeutic composition and method for treating infections with actinospectacin
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3732865A (en) 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4034756A (en) 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
BE795516A (en) 1972-02-17 1973-08-16 Ciba Geigy PREPARATIONS OF OILY AND INJECTABLE PEPTIDES AND PROCESS FOR THEIR PREPARATION
US3797492A (en) 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3995632A (en) 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
DE2528516A1 (en) 1974-07-05 1976-01-22 Sandoz Ag NEW GALENIC PREPARATION
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4078060A (en) 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4243030A (en) 1978-08-18 1981-01-06 Massachusetts Institute Of Technology Implantable programmed microinfusion apparatus
US4305927A (en) 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
AU546785B2 (en) 1980-07-23 1985-09-19 Commonwealth Of Australia, The Open-loop controlled infusion of diabetics
US4350271A (en) 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US4340054A (en) 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US4455145A (en) 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0079143A3 (en) 1981-10-20 1984-11-21 Adnovum Ag Pseudoplastic gel transfer
EP0080879B1 (en) 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
US5004689A (en) 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4455143A (en) 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4753651A (en) 1982-08-30 1988-06-28 Alza Corporation Self-driven pump
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4552561A (en) 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4639244A (en) 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
DE3320583A1 (en) 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF
JPS6058915A (en) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd Lipid microcapsule preparation containing medicament
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
MX9203641A (en) 1983-12-16 1992-07-01 Genentech Inc RECOMBINANT GAMMA INTERFERONS THAT HAVE IMPROVED STABILITY AND BIOTECHNOLOGICAL METHODS FOR THEIR OBTAINING.
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4851228A (en) 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US5120832A (en) 1984-08-27 1992-06-09 Genentech, Inc. Distinct family of human leukocyte interferons
US4927687A (en) 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FI90990C (en) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Recombinant DNA molecule, transformed host organism, and method for producing interferon
US4655462A (en) 1985-01-07 1987-04-07 Peter J. Balsells Canted coiled spring and seal
JPS61189230A (en) 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd Etoposide preparation
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DE3607835A1 (en) 1986-03-10 1987-09-24 Boehringer Ingelheim Int HYBRID INTERFERONS, THEIR USE AS MEDICINAL PRODUCTS AND AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF ANTIBODIES AND THE USE THEREOF AND METHOD FOR THEIR PRODUCTION
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4755180A (en) 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
DE3636123A1 (en) 1986-10-23 1988-05-05 Rentschler Arzneimittel ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
DE3642096A1 (en) 1986-12-10 1988-06-16 Boehringer Ingelheim Int HORSE (GAMMA) INTERFERON
US5371089A (en) 1987-02-26 1994-12-06 Senetek, Plc Method and composition for ameliorating the adverse effects of aging
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
JPH0720866B2 (en) 1987-05-15 1995-03-08 三生製薬株式会社 Transdermal preparation containing eperisone or tolperisone or their salts
US4940465A (en) 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4874388A (en) 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5023088A (en) 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5938654A (en) 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4886668A (en) 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US5072070A (en) 1989-12-01 1991-12-10 Peter J. Balsells Device for sealing electromagnetic waves
US4934666A (en) 1988-04-25 1990-06-19 Peter J. Balsells Coiled spring electromagnetic shielding gasket
US5203849A (en) 1990-03-20 1993-04-20 Balsells Peter J Canted coil spring in length filled with an elastomer
US4964204A (en) 1988-04-25 1990-10-23 Peter J. Balsells Method for making a garter-type axially-resilient coil spring
US5108078A (en) 1988-04-25 1992-04-28 Peter J. Balsells Canted-coil spring loaded while in a cavity
EP0339544B1 (en) 1988-04-25 1993-09-22 Peter J. Balsells Garter spring with canted back angle located on outside diameter
US4974821A (en) 1988-04-25 1990-12-04 Peter J. Balsells Canted-coil spring with major axis radial loading
US5079388A (en) 1989-12-01 1992-01-07 Peter J. Balsells Gasket for sealing electromagnetic waves
US4830344A (en) 1988-04-25 1989-05-16 Peter J. Balsells Canted-coil spring with turn angle and seal
US4893795A (en) 1988-08-15 1990-01-16 Peter J. Balsells Radially loaded canted coiled spring with turn angle
US5160122A (en) 1990-03-20 1992-11-03 Peter J. Balsells Coil spring with an elastomer having a hollow coil cross section
US4961253A (en) 1988-04-25 1990-10-09 Peter J. Balsells Manufacturing method for canted-coil spring with turn angle and seal
US4907788A (en) 1988-04-25 1990-03-13 Peter J. Balsells Dual concentric canted-coil spring apparatus
US5117066A (en) 1988-04-25 1992-05-26 Peter J. Balsells Retaining and locking electromagnetic gasket
US4826144A (en) 1988-04-25 1989-05-02 Peter J. Balsells Inside back angle canted coil spring
US4915366A (en) 1988-04-25 1990-04-10 Peter J. Balsells Outside back angle canted coil spring
US4876781A (en) 1988-04-25 1989-10-31 Peter J. Balsells Method of making a garter-type axially resilient coiled spring
US5024842A (en) 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006346A (en) 1988-04-28 1991-04-09 Alza Corporation Delivery system
JP2794022B2 (en) 1988-11-11 1998-09-03 三生製薬株式会社 Transdermal preparation containing bunazosin or its salts
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5728088A (en) 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US4969884A (en) 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5234424A (en) 1988-12-28 1993-08-10 Alza Corporation Osmotically driven syringe
US4976966A (en) 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
US5288479A (en) 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5906816A (en) 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5219572A (en) 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5126142A (en) 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5290558A (en) 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
SE465950B (en) 1989-10-23 1991-11-25 Medinvent Sa Combination of an aggregate particle size, crystalline or freeze-dried drug with a pseudoplastic gel for preparation of an injectable preparation as well as a process for its preparation
EP0453555B1 (en) 1989-11-13 1993-10-06 Medicorp Holding S.A. Storage bottle containing a constituent of a medicinal solution
JPH03236317A (en) 1989-12-06 1991-10-22 Sansei Seiyaku Kk Dopamine derivative-containing percutaneous
US5030216A (en) 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5213809A (en) 1990-01-24 1993-05-25 Alza Corporation Delivery system comprising means for controlling internal pressure
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5122128A (en) 1990-03-15 1992-06-16 Alza Corporation Orifice insert for a ruminal bolus
US5120306A (en) 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5290271A (en) 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5180591A (en) 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234695A (en) 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5151093A (en) 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
US5161806A (en) 1990-12-17 1992-11-10 Peter J. Balsells Spring-loaded, hollow, elliptical ring seal
GB9027422D0 (en) 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
PT99989A (en) 1991-01-09 1994-05-31 Alza Corp BIODEGRADABLE AND COMPOSITION DEVICES FOR DIFFUSIBLE LIBERATION OF AGENTS
US5443459A (en) 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5861166A (en) 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
US5113938A (en) 1991-05-07 1992-05-19 Clayton Charley H Whipstock
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
EP0520119A1 (en) 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate New oral diclofenac composition
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5288214A (en) 1991-09-30 1994-02-22 Toshio Fukuda Micropump
YU87892A (en) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center INJECTIBLE LONG TERM RELEASE FORMULATIONS AND PROCEDURES FOR THEIR OBTAINING AND USE
DE69229881T2 (en) 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical DELAYED RELEASE TABLET
JPH07500264A (en) 1991-10-10 1995-01-12 アルザ・コーポレーション Osmotic drug delivery device with hydrophobic wall material
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
DE4137649C2 (en) * 1991-11-15 1997-11-20 Gerhard Dingler Component
AU3136293A (en) 1991-11-15 1993-06-15 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5200195A (en) 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5223265A (en) 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5221278A (en) 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
EP0633907A1 (en) 1992-03-30 1995-01-18 Alza Corporation Additives for bioerodible polymers to regulate degradation
AU3941493A (en) 1992-03-30 1993-11-08 Alza Corporation Viscous suspensions of controlled-release drug particles
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
FR2690622B1 (en) 1992-04-29 1995-01-20 Chronotec Programmable ambulatory infusion pump system.
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5413672A (en) 1992-07-22 1995-05-09 Ngk Insulators, Ltd. Method of etching sendust and method of pattern-etching sendust and chromium films
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
GB9223146D0 (en) 1992-11-05 1992-12-16 Scherer Corp R P Vented capsule
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
SE9203594D0 (en) 1992-11-30 1992-11-30 Christer Nystroem DISPERSA SYSTEM MEDICINAL PRODUCT
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
AU6410494A (en) 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
US5514110A (en) 1993-03-22 1996-05-07 Teh; Eutiquio L. Automatic flow control device
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5639477A (en) 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
JPH08512054A (en) 1993-06-25 1996-12-17 アルザ・コーポレーション Inclusion of poly-N-vinylamide in transdermal system
US5498255A (en) 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
JP2700141B2 (en) 1993-09-17 1998-01-19 富士化学工業株式会社 Calcium hydrogen phosphate, its production method and excipient using the same
KR960704579A (en) 1993-09-29 1996-10-09 에드워드 엘. 만델 Monoglyceride / lactate Ester Permeation Enhancer for Oxybutynin
US5540665A (en) 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
ES2183865T3 (en) 1994-02-04 2003-04-01 Lipocore Holding Ab PREPARATIONS OF DOUBLE LAYER OF GALACTOLIPIDO CONTAINING DIGALACTOSILDIACILGLICEROL.
US5697975A (en) * 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
JP4001379B2 (en) 1994-03-07 2007-10-31 インペリアル カレッジ オブ サイエンス，テクノロジー アンド メディシン Use of interferon subtypes in the preparation of drugs to treat viral infections
EP0768867B1 (en) 1994-06-13 2002-10-09 Alza Corporation Dosage form for administering drug in liquid formulation
NL9401150A (en) 1994-07-12 1996-02-01 Nederland Ptt Method for presenting on a receiving side a first number of video signals originating from a transmitting side, as well as a system, as well as a transmitter, as well as a network, and also a receiver.
ES2153485T3 (en) 1994-07-13 2001-03-01 Alza Corp COMPOSITION AND PROCEDURE THAT INCREASES THE PERCUTANEOUS DIFFUSION BY ELECTROTRANSPORT OF A SUBSTANCE.
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5595759A (en) 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
DE69529572T2 (en) * 1994-11-10 2003-06-18 Univ Kentucky Res Foundation L IMPLANTABLE REFILLABLE DEVICE WITH CONTROLLED RELEASE FOR ADMINISTERING MEDICINAL SUBSTANCES DIRECTLY ON AN INNER PART OF THE BODY
FR2731150B1 (en) 1995-03-03 1997-04-18 Oreal USE OF AMPHIPHILIC COMPOUNDS AS A THICKENING AGENT FOR NON-AQUEOUS MEDIA
US5700583A (en) 1995-03-06 1997-12-23 Ethicon, Inc. Hydrogels of absorbable polyoxaesters containing amines or amido groups
US6403655B1 (en) 1995-03-06 2002-06-11 Ethicon, Inc. Method of preventing adhesions with absorbable polyoxaesters
US5962023A (en) 1995-03-06 1999-10-05 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US5597579A (en) 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
US6147168A (en) 1995-03-06 2000-11-14 Ethicon, Inc. Copolymers of absorbable polyoxaesters
US5859150A (en) 1995-03-06 1999-01-12 Ethicon, Inc. Prepolymers of absorbable polyoxaesters
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US5648088A (en) 1995-03-06 1997-07-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amide groups
US6100346A (en) 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US5464929A (en) 1995-03-06 1995-11-07 Ethicon, Inc. Absorbable polyoxaesters
US5595751A (en) 1995-03-06 1997-01-21 Ethicon, Inc. Absorbable polyoxaesters containing amines and/or amido groups
US5844017A (en) 1995-03-06 1998-12-01 Ethicon, Inc. Prepolymers of absorbable polyoxaesters containing amines and/or amido groups
US5618552A (en) 1995-03-06 1997-04-08 Ethicon, Inc. Absorbable polyoxaesters
US5607687A (en) 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
KR100404293B1 (en) 1995-05-02 2004-02-18 다이쇼 세이야꾸 가부시끼가이샤 Composition for Oral Administration
US5939286A (en) 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
TR199701541T1 (en) 1995-06-06 1998-03-21 F.Hoffmann-La Roche Ag Pharmaceutical composition containing proteinase inhibitor and monoglyceride.
AU703593B2 (en) 1995-06-07 1999-03-25 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6572879B1 (en) 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5690952A (en) 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5782396A (en) * 1995-08-28 1998-07-21 United States Surgical Corporation Surgical stapler
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
GB9521125D0 (en) 1995-10-16 1995-12-20 Unilever Plc Cosmetic composition
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
GB9521805D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Solubilisation methods
ES2192221T3 (en) 1995-10-30 2003-10-01 Oleoyl Estrone Developments S MONOESTERS OF STROGEN OLEATE FOR THE TREATMENT OF OBESITY OR OVERWEIGHT.
CA2329474C (en) * 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AUPN723395A0 (en) * 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
AU2526497A (en) 1996-02-02 1997-08-22 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
RU2189221C2 (en) 1996-02-02 2002-09-20 Элзэ Копэрейшн Method and device for administering active substance and method for treating prostate carcinoma patients
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JPH09241153A (en) 1996-03-04 1997-09-16 Q P Corp Lipid emulsion for intravenous injection
JP2000506160A (en) 1996-03-08 2000-05-23 ゼネカ リミテッド Azorobenzazepine derivatives as neurologically active agents
EP0904373A1 (en) 1996-03-14 1999-03-31 The Immune Response Corporation Targeted delivery of genes encoding interferon
US5703200A (en) 1996-03-15 1997-12-30 Ethicon, Inc. Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6074673A (en) 1996-04-22 2000-06-13 Guillen; Manuel Slow-release, self-absorbing, drug delivery system
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US6767887B1 (en) 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
DE69725745D1 (en) 1996-06-05 2003-11-27 Ashmont Holdings Ltd INJECTABLE COMPOSITIONS
DE29610419U1 (en) 1996-06-14 1996-10-24 Filtertek Sa Gravity infusion device for medical infusions
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
ES2201306T3 (en) 1996-07-03 2004-03-16 Alza Corporation NON-WATERPROOF PROEP PEPTIDIC FORMULATIONS.
ES2259746T3 (en) 1996-07-15 2006-10-16 Alza Corporation NEW FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FLUOXETINA.
AR008789A1 (en) 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
EP0966297B2 (en) 1996-08-08 2013-02-27 Amylin Pharmaceuticals, Inc. Regulation of gastrointestinal motility
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp
EP0934078B1 (en) 1996-10-24 2002-12-18 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
US5817129A (en) 1996-10-31 1998-10-06 Ethicon, Inc. Process and apparatus for coating surgical sutures
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
DE19646392A1 (en) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
US5928666A (en) 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
ATE245042T1 (en) 1996-11-15 2003-08-15 Alza Corp OSMOTIC DELIVERY SYSTEM AND METHOD FOR INCREASE PERFORMANCE AND IMPROVE THE INITIAL EFFECT OF OSMOTIC DELIVERY SYSTEMS
GB9626513D0 (en) 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
ES2158611T3 (en) 1996-12-20 2001-09-01 Alza Corp COMPOSITION IN INJECTABLE GEL WITH RETARD EFFECT AND PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION.
DE122007000044I2 (en) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD CONSUMPTION
JP2001511128A (en) 1997-01-28 2001-08-07 ファルマシア・アンド・アップジョン・カンパニー Lyophilized product of lipid complex of water-insoluble porphyrin
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
US5874388A (en) 1997-04-02 1999-02-23 Dow Corning Corporation Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US6127520A (en) 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
JP2001524958A (en) 1997-04-17 2001-12-04 ジーエス ディベロップメント アクティエボラーグ A novel liquid crystal based bioadhesive drug delivery system
WO1998049321A2 (en) 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
MY125870A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
ATE248583T1 (en) 1997-09-29 2003-09-15 Nektar Therapeutics STABILIZED PREPARATIONS USABLE IN DOSAGE INHALERS
JPH11100353A (en) 1997-09-29 1999-04-13 Esupo Kk Refined and deodorized liquid ester wax and its composition
US6133429A (en) 1997-10-03 2000-10-17 Becton Dickinson And Company Chromophores useful for the preparation of novel tandem conjugates
DK1032587T4 (en) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc New exendin agonist compounds
AU761577C (en) 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
US6368612B1 (en) 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells
DK1041975T3 (en) 1997-12-22 2002-11-04 Alza Corp Speed-controlling membranes for controlled drug delivery devices
CA2316949A1 (en) 1997-12-29 1999-07-08 Alza Corporation Implanter device for subcutaneous implants
DE69822208T2 (en) 1997-12-29 2005-04-28 Alza Corp., Mountain View OSMOTIC ADMINISTRATION SYSTEM WITH PUSHROOM RESTRAINT MECHANISM
JP4494629B2 (en) 1997-12-30 2010-06-30 インターシア セラピューティクス，インコーポレイティド Beneficial agent supply system with membrane plug
ATE248002T1 (en) * 1997-12-31 2003-09-15 Alza Corp SYSTEM FOR MONITORING AN OSMOTIC DRUG DELIVERY DEVICE
US20040024068A1 (en) 1998-01-23 2004-02-05 Trustees Of Tufts College Antimicrobial compounds
IT1298575B1 (en) 1998-02-06 2000-01-12 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
DE69936446T2 (en) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego INOTROPIC AND DIETIC EFFECTS OF EXENDIN AND GLP-1
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6224577B1 (en) 1998-03-02 2001-05-01 Medrad, Inc. Syringes and plungers for use therein
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
EP0984039A4 (en) 1998-03-12 2002-01-02 Daicel Chem Lactone-containing resin composition, molded object thereof, and film
US6029361A (en) 1998-03-25 2000-02-29 Ultratech Stepper, Inc. Air-guage nozzle probe structure for microlithographic image focusing
US6074660A (en) 1998-04-20 2000-06-13 Ethicon, Inc. Absorbable polyoxaesters containing amines and/ or amido groups
TW586944B (en) 1998-05-29 2004-05-11 Sumitomo Pharma Controlled release agent having a multi-layer structure
MXPA00012286A (en) 1998-06-12 2002-10-17 Bionebraska Inc GLUCAGON-LIKE PEPTIDE-1 IMPROVES beta-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE.
US6472512B1 (en) 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
US7390637B2 (en) 1998-07-21 2008-06-24 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
NZ510020A (en) 1998-09-09 2003-06-30 Alza Corp Membrane coated capsule for sustained release of a drug formulation, and a granulated composition, in liquid form
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6248112B1 (en) * 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
NZ511465A (en) 1998-11-02 2003-10-31 Alza Corp Controlled delivery of active agents
WO2000029206A1 (en) 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ295891B6 (en) 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application GLP-1 analogues substituted in position 35, their use and pharmaceutical compositions in which the analogues are comprised
JP2002532406A (en) 1998-12-17 2002-10-02 アルザ・コーポレーション Conversion of liquid-filled gelatin capsules into controlled-release systems with composite coatings
CN1158068C (en) 1998-12-23 2004-07-21 安姆根有限公司 Polyol/oil suspensions for the sustained release of proteins
US6433144B1 (en) * 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
WO2000039280A2 (en) 1998-12-31 2000-07-06 Viragen, Inc. Leukocyte-derived interferon preparations
CA2356860C (en) 1998-12-31 2006-11-07 Alza Corporation Osmotic delivery system having space efficient piston
WO2000040273A2 (en) 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
US6703225B1 (en) 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
CA2356706C (en) 1999-01-14 2014-09-30 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
CN100425284C (en) 1999-01-14 2008-10-15 安米林药品公司 Methods for glucagon suppression
CA2361424C (en) 1999-02-08 2009-04-28 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
WO2000062799A1 (en) 1999-04-19 2000-10-26 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
MXPA01011343A (en) 1999-05-07 2002-06-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same.
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20030059376A1 (en) 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
CA2375914A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
JP2003501375A (en) 1999-06-04 2003-01-14 アルザ・コーポレーション Implantable gel composition and method of manufacture
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6436091B1 (en) * 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001043528A2 (en) 1999-12-17 2001-06-21 Durect Corporation Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide
DE60023361T2 (en) 1999-12-21 2006-04-27 Alza Corp., Mountain View VALVE FOR OSMOTIC DEVICES
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6472060B1 (en) 2000-01-19 2002-10-29 Seco Tools Ab Coated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
MXPA02009031A (en) 2000-03-14 2004-08-19 Amylin Pharmaceuticals Inc Effects of glucagon like peptide 1 (7 36) on antro pyloro duodenal motility.
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
EP1274459B1 (en) 2000-04-19 2005-11-16 Genentech, Inc. Sustained release formulations comprising growth hormone
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
JP2001357075A (en) 2000-04-27 2001-12-26 El-Con System Co Ltd System and method for calculating quantity of materials while utilizing two-dimensional cad interface
AU6323001A (en) 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7084243B2 (en) 2000-06-16 2006-08-01 Eli Lilly And Company Glucagon-like peptide-1 analogs
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
AU2001296770A1 (en) 2000-10-06 2002-04-15 Durect Corporation Devices and methods for management of inflammation
AU2587002A (en) 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
EP1335704A2 (en) 2000-11-16 2003-08-20 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
CA2429945A1 (en) 2000-11-29 2002-06-06 Durect Corporation Devices and methods for controlled delivery from a drug delivery device
US20020165286A1 (en) 2000-12-08 2002-11-07 Hanne Hedeman Dermal anti-inflammatory composition
CA2431173A1 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
JP2004515533A (en) 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド Peptide YY and peptide YY agonist for treating metabolic disorders
IN188924B (en) 2001-03-01 2002-11-23 Bharat Serums & Vaccines Ltd
EP1379197A4 (en) 2001-03-23 2009-06-03 Durect Corp Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
US6514517B2 (en) 2001-06-20 2003-02-04 Ethicon, Inc. Antimicrobial coatings for medical devices
US7318931B2 (en) 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
ES2284871T3 (en) 2001-06-22 2007-11-16 Pfizer Products Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF LITTLE SOLUBLE PHARMACO AND A SOLUBILITY POTENTIATING POLYMER.
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
US20030138403A1 (en) * 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
JP2004535464A (en) 2001-07-20 2004-11-25 インターミューン インコーポレイテッド How to treat liver fibrosis
EP2275117B1 (en) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
US7101843B2 (en) 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
MXPA04002476A (en) 2001-09-14 2004-05-31 Anthony A Boiarski Microfabricated nanopore device for sustained release of therapeutic agent.
ATE443513T1 (en) 2001-09-17 2009-10-15 Durect Corp DEVICE AND METHOD FOR ACCURATE DELIVERY OF AN ACTIVE SUBSTANCE
ATE419863T1 (en) 2001-09-24 2009-01-15 Imp Innovations Ltd PYY3-36 FOR REDUCING OR PREVENTING OBESITY
CN1738635A (en) 2001-10-05 2006-02-22 印特缪恩股份有限公司 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
US20040142902A1 (en) 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
DE60237721D1 (en) 2001-11-09 2010-10-28 Intarcia Therapeutics Inc COMBINATION THERAPY WITH OMEGA INTERFERON FOR THE TREATMENT OF HEPATITIS C VIRUS OR YELLOW VIRUS INFECTIONS
MXPA04004664A (en) 2001-11-14 2004-09-10 Alza Corp Injectable depot composition.
NZ533435A (en) 2001-11-14 2007-10-26 Alza Corp Injectable depot compositions and uses thereof
CA2467239A1 (en) 2001-11-14 2003-05-22 Alza Corporation Catheter injectable depot compositions and uses thereof
DE10159217A1 (en) 2001-11-27 2003-06-05 Schering Ag 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations
US20030108608A1 (en) 2001-12-12 2003-06-12 Erik Laridon Thermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver
IL162294A0 (en) 2001-12-19 2005-11-20 Alza Corp Formulation & dosage form for the controlled delivery of therapeutic agents
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB2386066A (en) 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
GB0204722D0 (en) 2002-02-28 2002-04-17 Norferm Da Method
CA2484052C (en) 2002-04-11 2011-06-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
CN1668279A (en) 2002-06-17 2005-09-14 阿尔萨公司 Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE376854T1 (en) 2002-06-26 2007-11-15 Alza Corp MINIMALLY FORGIVE VOLUME EFFICIENT PISTON FOR OSMOTIC DRUG DELIVERY SYSTEMS
US7177526B2 (en) 2002-06-28 2007-02-13 Intel Corporation System and method for improving audio during post-production of video recordings
IL166418A0 (en) 2002-07-31 2006-01-15 Alza Corp Injectable depot compositions and uses thereof
CA2494400A1 (en) 2002-07-31 2004-02-05 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
ES2320754T3 (en) 2002-10-22 2009-05-28 Waratah Pharmaceuticals, Inc. TREATMENT OF DIABETES.
MXPA05004927A (en) 2002-11-06 2005-09-08 Alza Corp Controlled release depot formulations.
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
BR0317421A (en) 2002-12-19 2005-11-08 Alza Corp Stable non-aqueous single phase gels and formulations for release from an implantable device
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2004238392A (en) 2003-01-14 2004-08-26 Nipro Corp Stabilized proteinic preparation
WO2004075349A2 (en) 2003-02-18 2004-09-02 Medconx, Inc. Male medical device electrical connector with engineered friction fit
JP2006521897A (en) 2003-03-31 2006-09-28 アルザ・コーポレーション Osmotic pump with means for dissipating internal pressure
KR20060002922A (en) 2003-03-31 2006-01-09 알자 코포레이션 Non-aqueous single phase vehicles and formulations utilizing such vehicles
AU2004227986A1 (en) 2003-03-31 2004-10-21 Alza Corporation Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
WO2004101017A2 (en) 2003-05-16 2004-11-25 Blue Membranes Gmbh Medical implants comprising biocompatible coatings
EP1631308B1 (en) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
CN1822816A (en) 2003-05-30 2006-08-23 阿尔萨公司 Implantable elastomeric depot compositions and uses thereof
JP4936884B2 (en) 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー／エス Stabilized pharmaceutical peptide composition
US8491571B2 (en) 2003-06-12 2013-07-23 Cordis Corporation Orifice device having multiple channels with varying flow rates for drug delivery
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
BRPI0414941A (en) 2003-09-30 2006-11-07 Alza Corp osmotically driven active agent dispensing device providing an upward release profile
CA2537811A1 (en) 2003-10-31 2005-05-19 Alza Corporation Osmotic pump with self-retaining, fast-start membrane plug
CA2545027A1 (en) 2003-11-06 2005-05-26 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7780973B2 (en) 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
CA2555877C (en) 2004-02-11 2015-11-24 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
MXPA06011924A (en) 2004-04-15 2007-06-11 Alkermes Inc Polymer-based sustained release device.
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20090042781A1 (en) 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
JP5244388B2 (en) 2004-08-18 2013-07-24 ウオーターズ・テクノロジーズ・コーポレイシヨン Apparatus and method for generating or carrying fluid under pressure and seal member used in the apparatus
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
WO2006052608A2 (en) 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006074051A2 (en) 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
WO2006081279A2 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20060216242A1 (en) 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
EP2361630A1 (en) 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantable drug delivery device comprising particles and an osmotic pump
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
WO2006105527A2 (en) 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2006110551A2 (en) 2005-04-08 2006-10-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
WO2006111169A1 (en) 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
US9233203B2 (en) 2005-05-06 2016-01-12 Medtronic Minimed, Inc. Medical needles for damping motion
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US9447781B2 (en) 2005-07-22 2016-09-20 University Of Utah Research Foundation Osmotically driven dispense pump and related components for use in high pressure applications
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5693817B2 (en) 2005-08-19 2015-04-01 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc Diabetes treatment and weight loss
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
ES2586236T3 (en) 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedures for administering hypoglycemic agents
JP2009519949A (en) 2005-12-16 2009-05-21 アミリン・ファーマシューティカルズ，インコーポレイテッド Compositions and methods for the treatment of obesity and related metabolic disorders
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
CN101400363B (en) 2006-01-18 2012-08-29 昌达生物科技公司 Pharmaceutical compositions with enhanced stability
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
CA2649932A1 (en) 2006-05-02 2007-11-15 Actogenix Nv Microbial intestinal delivery of obesity related peptides
US8299024B2 (en) 2006-05-12 2012-10-30 Amylin Pharmaceuticals, Llc Methods to restore glycemic control
CN101453982B (en) 2006-05-30 2011-05-04 精达制药公司 Two-piece, internal-channel osmotic delivery system flow modulator
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
KR20140109509A (en) 2006-07-11 2014-09-15 큐피에스 엘엘씨 Pharmaceutical compositions for sustained release delivery of peptides
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
RU2440097C2 (en) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it
US8236760B2 (en) 2007-04-27 2012-08-07 Cedars-Sinsai Medical Center Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
CA2714506C (en) 2008-02-08 2016-06-07 Qps Llc Composition for sustained release delivery of proteins or peptides
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US9186502B2 (en) 2008-02-14 2015-11-17 Enteromedics Inc. Treatment of excess weight by neural downregulation in combination with compositions
US20110046071A1 (en) 2008-03-05 2011-02-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
EP3210474B1 (en) 2008-09-17 2020-11-18 Chiasma, Inc. Pharmaceutical compositions comprising polypeptides and related methods of delivery
NZ592113A (en) 2008-10-15 2012-04-27 Intarcia Therapeutics Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Oxyntomodulin peptide analogue ‎
US8263554B2 (en) 2010-06-09 2012-09-11 Amylin Pharmaceuticals, Inc. Methods of using GLP-1 receptor agonists to treat pancreatitis
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers

Also Published As

Publication number Publication date
US8257691B2 (en) 2012-09-04
AR046844A1 (en) 2005-12-28
JP2007527869A (en) 2007-10-04
EP2116230A3 (en) 2010-09-29
IL175606A (en) 2014-04-30
US20110208168A1 (en) 2011-08-25
US20050112188A1 (en) 2005-05-26
EP1689363A2 (en) 2006-08-16
WO2005048952A3 (en) 2005-12-29
AU2004291162B2 (en) 2009-07-30
PE20050926A1 (en) 2005-11-08
TW200534863A (en) 2005-11-01
US20100112070A1 (en) 2010-05-06
BRPI0416613A (en) 2007-01-16
IL175606A0 (en) 2006-09-05
JP4824574B2 (en) 2011-11-30
EP2116230A2 (en) 2009-11-11
MXPA06005565A (en) 2006-08-11
US20170319470A1 (en) 2017-11-09
US20110195097A1 (en) 2011-08-11
KR20060123160A (en) 2006-12-01
NZ547079A (en) 2009-03-31
WO2005048952A2 (en) 2005-06-02
US7964183B2 (en) 2011-06-21
US7731947B2 (en) 2010-06-08
US8398967B2 (en) 2013-03-19
NO20062867L (en) 2006-08-17
AU2004291162A1 (en) 2005-06-02
US20130052237A1 (en) 2013-02-28
EP1689363A4 (en) 2009-07-01
US9724293B2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
CA2546321A1 (en) Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
JP3676976B2 (en) Control of the amount of drug encapsulated in multivesicular liposomes
Fatouros et al. Effect of amphiphilic drugs on the stability and zeta-potential of their liposome formulations: a study with prednisolone, diazepam, and griseofulvin
JP3940177B2 (en) Use of neutral lipids to modify in vivo release from multivesicular liposomes
Thombre et al. Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients
JP2007527869A5 (en)
US6193998B1 (en) Method for producing liposomes with increased percent of compound encapsulated
US5552155A (en) Fusogenic lipsomes and methods for making and using same
FI95439C (en) A method of making biologically active multivesicular lipid vesicles or liposomes
AU689479B2 (en) Fusogenic liposomes and methods of making and using same
FI90396C (en) Process for the preparation of individual bilayer liposomes
JP2005505602A (en) Method for the production of liposome preparations having a predefined release profile
US5556580A (en) Liposome continuous size reduction method and apparatus
Ning et al. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antifungal drug clotrimazole
EP0450352B1 (en) Liposome formulations of immunomodulating drugs for the topical and aerosol administrations
EP0974364A1 (en) Method of inhibiting drug precipitation
TWI250877B (en) Process for producing liposome suspensions and products containing liposome suspensions produced thereby
Brandl et al. Vesicular phospholipid gels
CA1315198C (en) Liposome continuous size reduction method and apparatus
Sorasuchart Evaluation of polycarbophil coated liposomes and membrane permeation of free and liposomal drugs
US20050169978A1 (en) Wet-micro grinding

Legal Events

Date Code Title Description
EEER Examination request
AZWI Withdrawn application